R. Lyons
5 Papers
1 Citations
R. Lyons is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 3 publications.
Chat about Author
Papers
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
Andrew Yee,Omar Nadeem,Jacalyn Rosenblatt,Giada Bianchi,Elizabeth O'Donnell,Andrew R. Branagan,Cynthia C. Harrington,Emerentia Agyemang,Marilyn T. Gammon,Kathleen J. Lively,Lisette A. Packer,Z. Bernstein,R. Lyons,Manal Riadi,Sean Rowell,Cailin McVey,Amy C. Goguen,Nora Horick,Paul G. Richardson,Noopur Raje +19 more
TL;DR: Dara wKPd shows some of the highest response rates reported to date in relapsed/refractory MM, and builds on the efficacy of dara-based triplet regimens, with manageable toxicity and convenience of weekly K.
2
OAB-045: COVID-19 vaccine responsiveness in patients with Multiple Myeloma and Waldenström Macroglobulinemia
Andrew R. Branagan,Matthew Lei,Andrew Yee,Elizabeth O'Donnell,Jorge J. Castillo,Noopur Raje,Steven P. Treon,Catherine Flynn,Jill N. Burke,Cynthia C. Harrington,Emerentia Agyemang,Clifton C. Mo,Omar Nadeem,Paul G. Richardson,Allison Maebius,Chukwuamaka Onyewadume,Cristina Panaroni,Kirsten Meid,Z. Bernstein,R. Lyons,M. Waterman,Raquel Gallagher,Boris Juleg,G. Alter,Shayna Sarosiek +24 more
TL;DR: These preliminary data suggest impaired serologic responses following COVID-19 vaccines in patients with both MM and WM, and overall, WM patients showed more severe impairment of CO VID-19 S antibody responses.
1
P-042: Phase 1 dose-escalation study of sotatercept in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
Andrew Yee,Jacob P. Laubach,Ajay K. Nooka,Elizabeth O'Donnell,Cynthia C. Harrington,Emerentia Agyemang,Jill N. Burke,Marilyn T. Gammon,Kathleen J. Lively,Lisette Packer,James Bishop,Z. Bernstein,R. Lyons,Alexandra Wright,Cailin McVey,Paul G. Richardson,Noopur Raje +16 more
COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
Andrew R. Branagan,Matthew M Lei,Jenny S. Maron,Andrew J. Yee,Elizabeth K. O'Donnell,Jorge J. Castillo,N. Raje,Steven P. Treon,Catherine Flynn,Clifton C. Mo,Omar Nadeem,Paul G. Richardson,Cristina Panaroni,Kirsten Meid,Z. Bernstein,R. Lyons,Zachary R. Hunter,Maria Luisa Guerrera,Marilyn T. Gammon,Kathleen J. Lively,Lisette A. Packer,Matthew Waterman,Raquel Gallagher,Boris Juleg,Galit Alter,Shayna Sarosiek +25 more
TL;DR: The primary endpoint is SARS-CoV-2 spike protein (S) antibody (Ab) detection 28 days after final vaccination and functional serologic assessments and T-cell responses at 28 days, 6 months, 9 months, and 12 months following vaccination.
Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
Andrew R. Branagan,Matthew Lei,Clifton C. Mo,Andrew Yee,Elizabeth O'Donnell,Jorge J. Castillo,Omar Nadeem,Noopur Raje,Steven P. Treon,Paul G. Richardson,Rie Nakamoto-Matsubara,Kirsten Meid,Z. Bernstein,R. Lyons,Rakesh Verma,Zachary R. Hunter,Maria Luisa Guerrera,Catherine Flynn,Jill N. Burke,Cynthia C. Harrington,Emerentia Agyemang,Marilyn T. Gammon,Kathleen J. Lively,Lisette Packer,Nora Horick,Shayna Sarosiek +25 more
TL;DR: In this paper , the authors demonstrate the importance of COVID-19 vaccination boosting efforts for patients with multiple myeloma (MM) and Waldenström macroglobulinemia (WM).